Healthy stem cells can create benign tumours in jaw, USC study finds

A new study from the Ostrow School of Dentistry of University of Southern California published in Cell Stem Cell illustrates how changes in cell signaling can cause ordinary stem cells in the jaw to start forming benign but potentially harmful tumors.

Principal investigator Songtao Shi, professor at the Ostrow School's Center for Craniofacial Molecular Biology, said ossifying fibromas, the tumors focused on in the study, are benign but can grow aggressively and cause progressive enlargement of the jaw.

''The only treatment option for ossifying fibromas is surgical, which leads to major loss of vital tissues and challenging postsurgical reconstruction,'' Shi said. ''Quality of life is largely compromised. Thus, there is an urgent need to understand the underlying mechanism by which stem cells may contribute to the pathophysiology of orofacial benign tumors and to develop target-specific treatment.''

Shi and his collaborators uncovered a cellular signaling pathway that converts healthy mesenchymal stem cells in the jaw into ossifying fibroma mesenchymal stem cells (OFMSC), lessening their ability to make healthy bone tissue and greatly increasing the rate at which they multiply. The tumor stem cells display increased signaling activity with TGF-beta (TGF-b), a signaling protein already shown to be heavily tied to other craniofacial malformations.

Epigenetic upregulation - switching existing but inactive genes ''on'' - of the TGF-b cell signaling loop appears to increase the formation of ossifying fibroma tumors. Conversely, suppressing TGF-b signaling seems to quell the tumor's proliferation rate, Shi said.

While there is still much more investigation needed, Shi said he hopes that the findings have shed light on a way to stop the harmful growth of the tumors before risky surgery is needed.

''With an increased understanding of the mechanism of OFMSC, we can induce them to turn into normal jawbone MSC,'' he said. ''But before we can put this into clinical use, more translational research is needed.''

The study's authors included researchers from USC, the University of Pennsylvania, Baylor College of Medicine and the University of Iowa. The work was supported by grants from the National Institute of Dental and Craniofacial Research, the National Institutes of Health, the U.S. Department of Health & Human Services and a grant from the California Institute for Regenerative Medicine.